We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$362M
AUM Growth
+$9.59M
Cap. Flow
-$13M
Cap. Flow %
-3.59%
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$1.71M
2
BCAX
Bicara Therapeutics
BCAX
+$1.25M
3
CMPX icon
Compass Therapeutics
CMPX
+$1.09M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$1.02M
5
INGN icon
Inogen
INGN
+$992K

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.17M
2
MRUS
Merus
MRUS
+$2.96M
3
TSVT
2seventy bio
TSVT
+$2.12M
4
KALV
KalVista Pharmaceuticals
KALV
+$2.09M
5
RGLS
Regulus Therapeutics
RGLS
+$1.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
26
ProQR Therapeutics
PRQR
$240M
$3.2M 0.88%
1,567,561
– –
EWTX icon
27
Edgewise Therapeutics
EWTX
$4.13B
$3.12M 0.86%
238,140
+55,000
+30% +$793K
PODD icon
28
Insulet
PODD
$11.8B
$3.11M 0.86%
9,900
-2,000
-17% -$577K
IMVT icon
29
Immunovant
IMVT
$7.9B
$3.06M 0.85%
191,493
+21,497
+13% +$325K
ALKS icon
30
Alkermes
ALKS
$8.31B
$2.97M 0.82%
103,748
+9,548
+10% +$284K
BCAX
31
Bicara Therapeutics
BCAX
$1.69B
$2.94M 0.81%
317,001
+105,000
+50% +$1.25M
TELA icon
32
TELA Bio
TELA
$33.6M
$2.8M 0.77%
1,441,029
– –
KURA icon
33
Kura Oncology
KURA
$815M
$2.67M 0.74%
463,368
– –
DNLI icon
34
Denali Therapeutics
DNLI
$3.67B
$2.36M 0.65%
168,500
+40,600
+32% +$571K
CMPS
35
Compass Pathways
CMPS
$1.52B
$2.27M 0.63%
811,046
+100,000
+14% +$376K
ALGN icon
36
Align Technology
ALGN
$12.4B
$2.08M 0.57%
11,000
– –
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.24B
$1.96M 0.54%
218,255
-340,000
-61% -$3.17M
ATXS
38
DELISTED
Astria Therapeutics
ATXS
$1.74M 0.48%
324,775
+10,000
+3% +$48.5K
KROS icon
39
Keros Therapeutics
KROS
$200M
$1.74M 0.48%
130,316
– –
VKTX icon
40
Viking Therapeutics
VKTX
$3.8B
$1.71M 0.47%
64,516
– –
ARAY icon
41
Accuray
ARAY
$32.4M
$1.67M 0.46%
1,222,358
– –
BWAY
42
Brainsway
BWAY
$632M
$1.67M 0.46%
254,302
-58,764
-19% -$292K
ALLO icon
43
Allogene Therapeutics
ALLO
$632M
$1.56M 0.43%
1,380,118
– –
LXEO icon
44
Lexeo Therapeutics
LXEO
$329M
$1.52M 0.42%
378,083
– –
FHTX icon
45
Foghorn Therapeutics
FHTX
$270M
$1.41M 0.39%
300,452
-4,300
-1% -$18K
ITOS
46
DELISTED
iTeos Therapeutics
ITOS
$1.4M 0.39%
140,847
-72,500
-34% -$584K
ORIC icon
47
Oric Pharmaceuticals
ORIC
$1.1B
$1.37M 0.38%
135,271
-106,729
-44% -$717K
CMPX icon
48
Compass Therapeutics
CMPX
$340M
$1.37M 0.38%
+526,660
New +$1.09M
IMTX icon
49
Immatics
IMTX
$1.23B
$1.32M 0.36%
245,000
– –
ALEC icon
50
Alector
ALEC
$169M
$1.28M 0.35%
912,928
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, DAFNA Capital Management held 86 positions worth $362M, up 2.7% from $353M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

DAFNA Capital Management withdrew a net $13M in Q2 2025, closing 10 positions and reducing 21 holdings. Its most notable exit was 2seventy bio, an estimated $2.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Compass Therapeutics worth $1.37M.

  • DAFNA Capital Management's largest Q2 2025 buy was Compass Therapeutics: 526,660 shares worth $1.37M.
  • DAFNA Capital Management added most to Blueprint Medicines in Q2 2025, an estimated $1.71M increase.
  • DAFNA Capital Management's biggest Q2 2025 reduction was BioCryst Pharmaceuticals, cutting an estimated $3.17M.
  • DAFNA Capital Management fully exited 2seventy bio in Q2 2025, selling an estimated $2.12M.
  • DAFNA Capital Management's ten largest holdings make up 56% of its $362M portfolio in Q2 2025.
  • DAFNA Capital Management opened 3 new positions and closed 10 in Q2 2025.
  • DAFNA Capital Management's portfolio value rose 2.7% quarter-over-quarter to $362M.

Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.